Kazia granted 180-day extension by nasdaq to meet the minimum bid price requirement

Sydney , may 23, 2024 /prnewswire/ -- kazia therapeutics limited (nasdaq: kzia) (kazia or the company) received a letter on may 22, 2024 from nasdaq notifying the company that, while the company has not regained compliance with the minimum bid price requirement, nasdaq has determined that the company is eligible for an additional 180 calendar day period, or until november 18, 2024 (the "second compliance period"), to regain compliance with the minimum bid price requirement. as previously disclosed, on november 20, 2023, kazia therapeutics limited (the "company") received a deficiency notification from the listing qualifications staff of the nasdaq stock market llc ("nasdaq"), notifying the company that it was not in compliance with the minimum bid price requirement as set forth in nasdaq listing rule 5550(a)(2) (the "minimum bid price requirement").
NDAQ Ratings Summary
NDAQ Quant Ranking